AIDS Home > Egrifta Uses
People with HIV often have to deal with lipodystrophy as a result of their medications. Healthcare providers may recommend Egrifta as a treatment for this. The medication increases the release of growth hormone into the body, which is believed to aid in the breakdown of abdominal fat. Egrifta should not be used for weight loss, anti-aging, or to enhance athletic performance.
What Is Egrifta Used For?Egrifta™ (tesamorelin acetate) is an injectable medication approved to diminish excess abdominal body fat in people who have a condition called lipodystrophy as a result of the human immunodeficiency virus (HIV).
Lipodystrophy is a change in the way the body produces, uses, and stores fat. With this condition, fat often decreases in certain areas, especially the face, arms, legs, and buttocks. Also, fat can be built up in some areas, especially the stomach, breasts, and back of the neck. HIV medicines that are known to cause lipodystrophy are the protease inhibitors (PIs) and the nucleoside reverse transcriptase inhibitors (NRTIs).
As previously stated, Egrifta is approved to reduce abdominal fat (stomach fat) in people with lipodystrophy due to HIV medications. Thus, the effectiveness of Egrifta can be seen by measuring the distance around a person's waist. This medication is not approved for weight loss and will not cause weight loss.
How Does Egrifta Work?
Egrifta contains a human growth hormone-releasing factor (GRF), also known as growth hormone-releasing hormone (GHRH). In humans, this hormone is produced in the brain and acts to increase the production and release of growth hormone (GH).
Growth hormone is known to have both anabolic (building up of organ tissues) and lypolytic (breakdown of fatty tissue) effects. Though the effects of GH are extensive, the action of fat breakdown is believed to be responsible for the reduction in fatty tissue in the stomach.